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Lomustine is an oral alkylating drug commonly used for brain tumor patients. Recently, the lomustine-containing PCV polychemother-
apy regime (procarbazine, CCNU/lomustine, and vincristine) in combination with radiotherapy has become the standard of care for
anaplastic oligodendroglioma with 1p/19q codeletion and high-risk low-grade glioma. Here, we review the literature of all reported
cases of lomustine overdose, highlight complications by exemplifying a case of inadvertent lomustine overdose, and outline the man-
agement of this potential complication of outpatient PCV therapy.
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Background
Therapeutic options for recurrent glioblastoma are limited and
comprise second surgery, alkylating chemotherapy, and antian-
giogenic therapy.1 The alkylating agent lomustine is commonly
employed as the standard control drug for clinical trials in recur-
rent glioblastoma. Examples include the REGAL trial investigating
cediranib versus cediranib plus lomustine versus lomustine alone
(Clinical Trials.gov identifier NCT00777153), a phase III study of
enzastaurin versus lomustine in recurrent glioblastoma,2 or the
ongoing phase II EORTC 26101 study that explores the sequence
of bevacizumab and lomustine upon first recurrence in glioblasto-
ma (ClinicalTrials.gov identifier NCT01290939). Lomustine is also
being investigated for primary glioblastoma in combination with
temozolomide in the phase III CeTeG trial (ClinicalTrials.gov iden-
tifier NCT01149109). Recent long-term follow-up reports of the
RTOG 9402 and the EORTC 26951 trials suggested that PCV che-
motherapy (consisting of procarbazine, CCNU/lomustine, and vin-
cristine) in combination with radiotherapy (RT) prolongs overall
survival of patients with anaplastic oligodendrogliomas and oli-
goastrocytomas harboring 1p/19q codeletions.3,4 Median survival
of patients with codeleted tumors who were treated with RT plus
PCV was twice that of patients receiving RT alone (14.7 vs 7.3 y;
HR¼ 0.59; 95% CI, 0.37–0.95; P¼ .03).4 Furthermore, addition of
PCV to RT improved progression-free survival for patients with
high-risk low-grade gliomas.5 Thus, lomustine is a drug that is
commonly and probably even increasingly applied in the treat-
ment of gliomas. The drug is given orally on an outpatient basis
at a dose of 80–110 mg/m2 every 6 weeks.
Report of a Case
We report the case of a 71-year-old male patient with glioblasto-
ma of the right insula and temporal lobe. The methylguanine
methyl transferase (MGMT) gene promoter was not methylated,
and IDH-1 or IDH-2 mutations were not detected. Twenty-eight
days after partial resection of the tumor, the patient received
involved-field RT (6 MV photons, 5×2 Gy per week, 60.0 Gy)
with concomitant temozolomide (75 mg/m2, 140 mg per day).
Next, the patient received 2 cycles of adjuvant temozolomide (5
of 28 days; first cycle at 150 mg/m2, 345 mg; second cycle at
200 mg/m2, 460 mg). Upon disease progression after the second
cycle of temozolomide (Fig. 1A and B), the patient gave consent
for enrollment into the phase I RO-BP25389 trial (ClinicalTrials.gov
identifier NCT01308684) and received combined therapy of
bevacizumab and a humanized antibody against placental
growth factor (PlGF), RO-5323441. After initial radiological partial
response, the tumor recurred multifocally in the temporopolar
area and in the basal ganglia of the right hemisphere after
22 weeks. Thereafter, therapy with lomustine was planned
(110 mg/m2, 200 mg every 6 weeks). Despite detailed written
and oral instructions, a 30/30 score in the mini-mental status
exam, and minimal neuropsychological deficits, the patient con-
tacted us a few days later and reported that he had taken 200 mg
daily for 4 days. He was also taking antiemetic prophylaxis with
ondansetron and experienced no nausea or vomiting.
The patient was admitted for close monitoring on day 11 after
the first lomustine dose with a considerably reduced KPS as com-
pared with his previous consultation on day zero (60% vs 80%).
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The patient reported abdominal pain and cramps, which lasted
until day 13. Glutamic pyruvic transaminase (GPT), glutamine-
oxaloacetic transaminase (GOT), g-glutamyl transferase, and lac-
tic dehydrogenase were not elevated and remained normal
thereafter. An ultrasound of the abdomen on day 12 showed
no pathology except for previously known liver cysts that
had been stable in size and morphology over the past year.
From day 10 after starting lomustine, his hemoglobin, white
blood cell, and platelet counts dropped and did not recover
for 25 days (Fig. 2). The patient was put on granulocyte
colony-stimulating factor (G-CSF; 48 Mio IU) and systemic antibi-
otic prophylaxis with sulfamethoxazol p.o. (800 mg/d), trimetho-
prim p.o. (160 mg/d), and levofloxacin p.o. (1000 mg/d). Because
of the risk for intestinal necrosis and/or microlesions with lomus-
tine overdose, the patient’s gastrointestinal symptoms prompted
us to add metronidazole p.o. (1500 mg/d), gentamycin p.o.
(80 mg/d), and amphotericin B p.o. (200 mg/d) for intestinal
decontamination from days 11–25. We did not obtain autolo-
gous stem cells because impaired performance status and poor
prognosis precluded stem cell transplantation. From day 11 on,
Fig. 1. T1-weighted gadolinium-enhanced MRI sections. (A and B) Tumor progression after 2 cycles of adjuvant temozolomide (5/28 schedule).
Transverse sections postoperatively (A) and 155 days postoperatively (B). (C and D) Tumor stabilization upon lomustine overdose. Coronary sections
on day 3 (C) and on day 18 (D) relative to the first day of intake of 4 days times 200 mg lomustine. (E and F) Tumor progression on day 80 relative
to the first day of intake of 4 days times 200 mg lomustine. Coronary (E) and transverse (F) sections.
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the patient was put on N-acetylcystein p.o. (600 mg/d), which we
considered to have cytoprotective effects against lomustine-
induced organ toxicity.
On day 27, coagulase-negative staphylococci were detected in
the stool; thus, we put the patient on oral vancomycin (750 mg/
d). There was no increased body temperature or increase in the
frequency of bowel movements at any time, and C-reactive pro-
tein (CRP) was only slightly increased to 16.0 mg/L on day 27. The
patient remained stable, although severely myelosuppressed. He
received 6 thrombocyte transfusions in total on day 21, day 23,
and days 27–30, respectively, when thrombocyte counts dropped
below 20 000/mL. Metronidazole, levofloxacine, vancomycin, and
amphotericine B were stopped on day 37, and the patient was
discharged in reduced general condition and KPS 60% on day 41.
MRI performed on day 18 showed no tumor progression
(Fig. 1C and D), although the patient’s general condition had de-
clined clinically. No further chemotherapy was given. Until the
next visit on day 80, the KPS had dropped to 40%–50%, and the
patient developed a severe left sensorimotor hemisyndrome and
severe neuropsychological deficits with predominant hemineglect,
perseveration, and near-complete loss of short-term memory. An
MRI on day 80 showed severe multifocal tumor progression (Fig. 1E
and F). Palliative care was implemented, and the patient died
on day 137.
Review of the Literature
A literature review revealed 6 cases of inadvertent lomustine over-
dose, one of which was fatal (Table 1).6–10 All patients suffered
prolonged myelosuppression, as defined by thrombocyte counts
,100 000/mL, leukocyte counts ,2500/mL, absolute neutrophil
counts ,1500/mL, or hemoglobin ,90 g/L. Myelosuppression
occured as early as day 10–20. Severe abdominal pain was ob-
served in our patient and was reported in 2 other cases, one of
whom suffered inflammatory ileal necrosis.9 The cause of death
of one patient with lethal lomustine overdosewas not determined,
but central nervous system toxicity was suggested as a possibility.8
In our patient, no unexpected or severe complications beside pro-
longed and early myelosuppression occurred. While severe compli-
cations, including ileal necrosis and pulmonary toxicity, have been
reported from other patients with lomustine overdose,8,9manage-
ment of patients with lomustine overdose is determined by
diagnosis and prevention of infectious complications.
The underlying reason for lomustine overdosing has been re-
ported for one case in which a prescription error by the general
practitioner occurred.9 In all reported cases, patients were sup-
plied with lomustine for more than one dose. Although the rea-
sons for this practice remain elusive, prescription errors by
physicians or pharmacists are the most likely had causes. For the
present case, lomustine was exclusively available in boxes of
20 pills of 40 mg, and the patient stated that he had confused
dosing with temozolomide in the 5/28 regimen. The overrepresen-
tation of brain tumor patients among reported cases of in-
advertent lomustine intake suggests that impaired cognitive
functioning may have contributed to overdosing, although our pa-
tient had minimal neurocognitive deficits. Neither putative under-
lying suicidal nor self-medicating intentions have been reported.
Recommendations for Clinical Practice
Paramount in preventing harm of patients from lomustine over-
dose is to avoid supplying patients with more than the dose for
a single cycle at a time. Physicians prescribing lomustine should
be trained respectively, including reconfirming the single-dose
supply with the pharmacy and thorough providing patient
Fig. 2. (A–C) Time course of myelosuppression and supportive treatment
after lomustine overdose. The levels of leukocytes (A), hemoglobin (B),
and platelets (C) are shown. The days of lomustine intake are labeled by
crosses. The days of G-CSF administration (A) or platelet transfusions (C)
are indicated by arrowheads. The patient left the hospital on day 41.
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education. Electronic medical records that alert physicians in case
of prescription errors should also be standard in centers supplying
chemotherapy.
In cases of lomustine overdose, an initial assessment of the
risk of serious infectious complications according to the Infec-
tious Diseases Society of America (IDSA) criteria for patients
with neutropenia11 should guide the approach to therapy includ-
ing the need for inpatient admission and antibiotic therapy. Pa-
tients with an absolute neutrophil count (ANC) that is expected
to drop ,100/mL for .7 days (eg, patients with lomustine intake
of 800 mg or previous myelosuppression), or patients with signifi-
cant comorbidities are at a high risk for infectious complications.
Patients with severe neurological symptoms including epileptic
seizures should be admitted to hospital for close monitoring. Pa-
tients at low risk for infectious complications with no signs of in-
fection may bemanaged as outpatients if their general condition,
mental status, neurological symptoms, and social situation allow
for close monitoring and implementation of hygienic precautions,
as outlined below.
Hygienic precautions include initial dental examination and
treatment of putative intraoral foci, avoidance of crowds or public
transportation, removal of flowers or plants from the patient’s
rooms, no handshakes, disinfection of hands before and after
any contact with the patient, and avoidance of raw food. High-risk
patients should be treated with special precautions, including iso-
lation and use of single-use gowns, gloves, and masks, upon drop
of ANC ,100/mL or development of symptoms,.
Recommendations for monitoring include daily assessment
of vital parameters, physical examination including auscultation
of the lungs and oral and abdominal examination, laboratory
investigations including blood counts and CRP, and sampling
of body material upon development of fever or other clini-
cal symptoms. X-rays of the chest should be performed at the
initial assessment and upon development of pulmonary signs
or symptoms. An ultrasound or CT scan of the abdomen should
be performed upon development of gastrointestinal symptoms,
but rectal contrast application or colonoscopy should be omitted
because of the increased risk of intestinal perforation after
lomustine overdose.
High-risk patients should generally receive broad-spectrum
antibiotic prophylaxis that covers Pseudomonas species at least
until ANC has resolved to .500/mL or until infection-related
symptoms resolve and CRP is dropping (eg, with oral levofloxacin).
Antibiotic prophylaxis in neutropenic patients without fever is as-
sociated with lower all-cause mortality, reduced occurrence of
fever and infections, and lower risk of infection-related death
but increased gastrointestinal toxicities.12 Given lomustine-
associated intestinal toxicity and a possibly cumulative risk with
antibiotic-related gastrointestinal toxicity, the indication for anti-
biotic prophylaxis should be evaluated carefully in low-risk pa-
tients with lomustine overdose, but it should be implemented if
the expected duration of neutropenia,500/mL exceeds 7 days.11
Upon development of neutropenic fever, low-risk outpatients
should receive oral ciprofloxacin and oral amoxicillin/clavulanate,
or oral levofloxacin, whereas all high-risk patients and low-risk
patients developing symptoms as inpatients (.2 days after ad-
mission) should receive i.v. therapy with piperacillin/tazobactam,
carbapeneme, ceftazidime, or cefepime followed by specific
adjustments depending on persistence of symptoms, culture
tests, and infectious focus.11Ta
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Antibiotic prophylaxis should include prophylaxis against
Pneumocystis jirovecii with oral trimethoprim/sulfamethoxazole
in all patients if lymphocyte counts drop below 1000/mL, but
no antifungal or antiviral prophylaxis needs to be initiated in
asymptomatic patients. Intestinal decontamination with oral
metronidazole, gentamycin, and amphotericin B should only be
performed in patients with gastrointestinal pain or gastrointestinal
comorbidities.
The use of G-CSF for patients with chemotherapy-induced
myelosuppresion is under debate, mainly because no overall sur-
vival benefit has been shown for using G-CSF in the primary pro-
phylaxis of chemotherapy-induced neutropenic fever. However, a
meta-analysis that included 3493 patients treated in 17 random-
ized controlled trials demonstrated a 45% decrease in infection-
related mortality upon chemotherapy-induced leukopenia
(relative risk, 0.55; 95% CI, 0.33–0.90).13
We further recommend administration of N-acetylcysteine to
patients with lomustine overdose because N-acetylcystein may
limit organ toxicity by scavenging oxygen-derived free radicals
and restoring hepatic glutathione.14,15
We have concluded that lomustine overdose requires careful
evaluation and treatment of aplasia-related infectious complica-
tions and organ toxicity. We therefore recommend the measures
outlined in Table 2 to manage this potential life-threatening
condition.
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